Myriad Genetics Management

Management criteria checks 2/4

Myriad Genetics' CEO is Paul Diaz, appointed in Aug 2020, has a tenure of 3.75 years. total yearly compensation is $12.11M, comprised of 9% salary and 91% bonuses, including company stock and options. directly owns 0.63% of the company’s shares, worth $11.28M. The average tenure of the management team and the board of directors is 2.3 years and 4 years respectively.

Key information

Paul Diaz

Chief executive officer

US$12.1m

Total compensation

CEO salary percentage	9.0%
CEO tenure	3.8yrs
CEO ownership	0.6%
Management average tenure	2.3yrs
Board average tenure	4yrs

Recent management updates

Recent updates

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Mar 28

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Feb 02

Myriad Genetics receives expanded coverage in Japan for breast cancer diagnostic system

Aug 25

Are Investors Undervaluing Myriad Genetics, Inc. (NASDAQ:MYGN) By 50%?

Aug 05

Myriad Genetics Q2 2022 Earnings Preview

Aug 03

Myriad Genetics touts study results of GeneSight test on depression remission rates

Jul 12

CEO Compensation Analysis

How has Paul Diaz's remuneration changed compared to Myriad Genetics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$12m	US$1m	-US$263m
Sep 30 2023	n/a	n/a	-US$274m
Jun 30 2023	n/a	n/a	-US$248m
Mar 31 2023	n/a	n/a	-US$146m
Dec 31 2022	US$11m	US$1m	-US$112m
Sep 30 2022	n/a	n/a	-US$77m
Jun 30 2022	n/a	n/a	-US$18m
Mar 31 2022	n/a	n/a	-US$8m
Dec 31 2021	US$13m	US$1m	-US$27m
Sep 30 2021	n/a	n/a	-US$57m
Jun 30 2021	n/a	n/a	-US$97m
Mar 31 2021	n/a	n/a	-US$148m
Dec 31 2020	US$16m	US$383k	-US$224m

Compensation vs Market: Paul's total compensation ($USD12.11M) is above average for companies of similar size in the US market ($USD5.66M).

Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.

CEO

Paul Diaz (61 yo)

3.8yrs

Tenure

US$12,108,359

Compensation

Mr. Paul J. Diaz serves as the Member of Advisory Board at Thornton Capital, LLC. He has been the Chief Executive Officer, President and Director of Myriad Genetics, Inc. since August 13, 2020. He serves a...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Paul Diaz	CEO, President & Director	3.8yrs	US$12.11m	0.63% $ 11.3m
Samraat Raha	Chief Operating Officer	less than a year	US$5.02m	no data
Dale Muzzey	Chief Scientific Officer	2.3yrs	US$2.23m	0.12% $ 2.2m
Mark Verratti	Chief Commercial Officer	6.8yrs	US$2.88m	0.33% $ 5.9m
Scott Leffler	Chief Financial Officer	less than a year	no data	no data
Natalie Munk	Principal Accounting Officer	1.9yrs	no data	0.049% $ 879.1k
Kevin Haas	Chief Technology Officer	3.3yrs	US$1.64m	0.15% $ 2.6m
Matthew Scalo	Senior Vice President of Investor Relations	no data	no data	no data
Glenn Farrell	Senior VP & Chief Marketing Officer	1.4yrs	no data	no data
Shereen Solaiman	Chief People Officer	1.2yrs	no data	0.0032% $ 56.6k
Thomas P. Slavin	Chief Medical Officer	4.2yrs	no data	no data
Margaret Ancona	Senior Vice President of Transformation & Chief of Staff to CEO	3.3yrs	no data	0.025% $ 443.1k

2.3yrs

Average Tenure

50yo

Average Age

Experienced Management: MYGN's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Paul Diaz	CEO, President & Director	3.8yrs	US$12.11m	0.63% $ 11.3m
Daniel Spiegelman	Independent Director	4yrs	US$437.99k	0.028% $ 501.3k
Paul Bisaro	Independent Director	1.6yrs	US$258.48k	0.019% $ 333.8k
Lee Newcomer	Independent Director	4.7yrs	US$447.99k	0.064% $ 1.1m
Daniel Skovronsky	Independent Director	3.8yrs	US$433.49k	0.061% $ 1.1m
Colleen Reitan	Independent Director	4.7yrs	US$443.49k	0.064% $ 1.1m
Heinrich Dreismann	Independent Director	13.9yrs	US$443.49k	0.11% $ 2.0m
S. Phanstiel	Independent Chair of the Board	14.7yrs	US$563.49k	0.14% $ 2.6m
Rashmi Kumar	Independent Director	3.7yrs	US$433.49k	0.060% $ 1.1m

4.0yrs

Average Tenure

63yo

Average Age

Experienced Board: MYGN's board of directors are considered experienced (4 years average tenure).

Myriad Genetics Management

Management criteria checks 2/4

Key information

Recent management updates

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

Executive VP notifies of intention to sell stock

Myriad Genetics, Inc. Appoints Samraat S. Raha as Chief Operating Officer, Effective as of December 11, 2023

Myriad Genetics Appoints Sam Raha as Chief Operating Officer, Effective December 11, 2023

Insufficient new directors

Recent updates

Myriad Genetics, Inc. to Report Q1, 2024 Results on May 07, 2024

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Consensus EPS estimates upgraded to US$0.93 loss

Price target increased by 8.9% to US$24.50

Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024

Full year 2023 earnings: EPS misses analyst expectations

Myriad Genetics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Myriad Genetics' Strategic Growth Fuels Bullish Outlook

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024

Myriad Genetics, Inc. (NasdaqGS:MYGN) agreed to acquire Select assets of Intermountain Precision Genomics.

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Consensus EPS estimates fall by 21%, revenue upgraded

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New minor risk - Shareholder dilution

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Myriad Genetics, Inc. Provides Financial Guidance for 2023 and 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP notifies of intention to sell stock

Myriad Genetics, Inc. Appoints Samraat S. Raha as Chief Operating Officer, Effective as of December 11, 2023

Myriad Genetics Appoints Sam Raha as Chief Operating Officer, Effective December 11, 2023

Myriad Genetics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Price target decreased by 8.2% to US$21.67

Bernstein Litowitz Berger & Grossmann LLP Proposes Settlement of Class Action Involving Persons Who Purchased or Acquired Myriad Genetics, Inc. Common Stock

Insufficient new directors

Consensus EPS estimates fall by 52%

Myriad Genetics Announces Enhancements to the Genesight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2023

Myriad Genetics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Myriad Genetics, Inc. Announces Inclusion of Breast Density to Myrisk(R) with Riskscore(R) Breast Cancer Risk Assessment

Independent Director notifies of intention to sell stock

Myriad Genetics, Inc. Appoints Adam Brufsky as Scientific Advisor

Consensus EPS estimates fall by 27%, revenue upgraded

Myriad Genetics, Inc. Revises Earnings Guidance for the Full Year of 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 7.7% to US$21.72

Calculating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Chief Operating Officer notifies of intention to sell stock

Chief Operating Officer notifies of intention to sell stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 24%

Executive VP notifies of intention to sell stock

Myriad Genetics, Inc. Hires Senior Leaders to Advance Commercial Growth Plans

Myriad Genetics, Inc. announces Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

High number of new directors

Price target decreased to US$20.44

Myriad Genetics Announces Urosuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-Driven Medical Information

Consensus EPS estimates fall by 103%

Price target decreased to US$22.19

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Myriad Genetics, Inc. (NasdaqGS:MYGN) acquired Gateway Genomics, LLC for approximately $110 million.

Myriad Genetics, Inc. Elects Paul M. Bisaro as New Board Member

High number of new directors

Myriad Genetics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Myriad: Trying To Find Its Footing In An Evolving Industry

Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer

Myriad Genetics receives expanded coverage in Japan for breast cancer diagnostic system

Price target increased to US$24.36

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2022

Are Investors Undervaluing Myriad Genetics, Inc. (NASDAQ:MYGN) By 50%?

Myriad Genetics Q2 2022 Earnings Preview

Myriad Genetics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Myriad Genetics touts study results of GeneSight test on depression remission rates

Myriad Genetics, Inc. Announces the Resignation of Dennis Langer as Director

Independent Director notifies of intention to sell stock